Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian… Read More
The establishment of Innovation Gateway, a high-quality incubator space for life-science companies at The London Cancer Hub in Sutton, is underway. This is a significant step in realising the aims of The London Cancer Hub, a partnership between the London Borough of Sutton and The Institute of Cancer Research, that… Read More
Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More
Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More
A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of… Read More
A new study by Novateur Ventures provides a comparative analysis of twelve Covid-19 vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global… Read More
Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More
The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, has announced the appointments of Dr Lynne Hughes and Dr James Summers as Venture Partners, bringing additional expertise in neuroscience research and development. Dr Jonathan Behr, Partner at The… Read More
Charles River Laboratories and Valence Discovery have teamed up to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimisation. Building on research done by Valence’s founding team at Mila, a deep learning research institute, the Valence platform enables the design of small… Read More
Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours,… Read More
Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More
Sanofi CEO Paul Hudson has outlined key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. The company’s commitment is based on: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees. “The pandemic… Read More
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More
Valneva, a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, has announced positive data for Part A of the Phase I/II clinical trial of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. Based on this data, the company plans… Read More
Researchers at the Francis Crick Institute and GSK are extending their collaboration to advance the discovery of new drug targets in a £11.5 million effort. This comes after receiving a ‘Prosperity Partnership’ grant from the Engineering and Physical Sciences Research Council (EPSRC) and matching funds from GSK. Together, the teams… Read More
Biotech company Novavax has announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase IIb trial in South Africa and its pivotal Phase… Read More
